Other inhibitors of p53 pathway interactions, with associated proteins in the pathway including MDM4 and PPMID-1, have relied on similar principles of trying to raise WT p53 in cells in order to decrease dysfunctional p53 transcription driving tumor burden (Esfandiari et al., 2016; Pishas et al., 2015). Here, TP53 is linked to neoplasm.